This Week in Urology — Jul 3, 2026

Welcome to This Week in Urology. This week we're covering 10 notable papers spanning advanced therapeutics in renal cell carcinoma, innovations in stone management, risk stratification and interventions in prostate cancer, and critical survivorship and monitoring strategies in bladder and penile malignancies. Let's dive in.

We begin in the realm of advanced renal oncology, where the therapeutic landscape for clear-cell renal cell carcinoma is rapidly shifting toward targeting the hypoxia-inducible factor two-alpha pathway. In a major phase three, double-blind trial published in The New England Journal of Medicine, researchers evaluated the efficacy of combining the hypoxia-inducible factor two-alpha inhibitor belzutifan with the standard adjuvant immunotherapy pembrolizumab [1]. The LITESPARK-022 trial randomized 1,841 patients who had undergone nephrectomy and were at increased risk for recurrence into two equal arms: one receiving pembrolizumab and belzutifan, and the other receiving pembrolizumab and a placebo. After a median follow-up of twenty-eight point four months, the combination therapy demonstrated a significant improvement in disease-free survival, reducing the risk of recurrence or death by twenty-eight percent. The estimated two-year disease-free survival rate was eighty point seven percent in the combination group compared to seventy-three point seven percent in the monotherapy group. However, overall survival did not differ significantly between the groups at this interim analysis, with two-year survival rates exceeding ninety-five percent in both arms. Clinicians must carefully weigh these efficacy gains against a substantial increase in toxicity, as grade three or higher adverse events occurred in over fifty-two percent of patients receiving the combination compared to thirty percent of those on pembrolizumab alone. Complementing these adjuvant findings, a study published in Nature introduces casdatifan, a novel, orally bioavailable, potent, and selective hypoxia-inducible factor two-alpha inhibitor evaluated in the ARC-20 study for patients with refractory metastatic clear-cell renal cell carcinoma [3]. In this dose-expansion cohort of one hundred twenty-seven patients, monotherapy with casdatifan produced an objective response rate of thirty-one percent overall, which rose to thirty-five percent in the cohort receiving one hundred milligrams daily. The median progression-free survival was twelve point two months for the entire cohort. Crucially, the study established a clear biological link between on-target pathway modulation and clinical efficacy, showing that greater maximal reductions in serum erythropoietin were significantly associated with higher response rates, lower rates of progressive disease, and prolonged progression-free survival. This molecular correlation, combined with a low treatment discontinuation rate of just three percent due to adverse events, positions casdatifan as a highly promising agent in the refractory setting.

Moving from oncology to endourology, our next theme examines how active suction technologies are transforming the management of upper urinary tract stones and improving patient safety. Writing in the BJU International, investigators presented a randomized controlled trial comparing flexible ureteroscopy utilizing a flexible and navigable suction ureteral access sheath, known as FANS, against mini-percutaneous nephrolithotomy for the treatment of large upper urinary tract stones measuring two to three centimeters [2]. In this trial of three hundred twenty-six patients, the FANS approach achieved immediate and one-month stone-free rates that were entirely comparable to the percutaneous approach. While the operative duration was longer in the FANS group, this was offset by several key clinical benefits, including significantly less hemoglobin loss and a shorter hospital stay. A prespecified subgroup analysis of stones measuring two to two and a half centimeters revealed even more compelling results, where the FANS technique demonstrated a non-inferior stone-free rate without a significantly longer operative time, suggesting it may be the preferred, less invasive option for this specific stone size. The clinical benefits of active suctioning are further validated by a systematic review and meta-analysis published in the World Journal of Urology, which compared suction-assisted percutaneous nephrolithotomy against conventional percutaneous nephrolithotomy [5]. Analyzing eight studies with over eleven hundred patients, the authors found that suction-assisted systems maintained significantly lower intrarenal pressures, ranging from two point seven to sixteen point nine millimeters of mercury, compared to fifteen point four to over thirty millimeters of mercury in the conventional groups. By effectively preventing prolonged episodes of elevated intrarenal pressure, the suction-assisted cohorts experienced significantly lower risks of postoperative fever and Clavien-Dindo grade two or higher complications, alongside shorter operative times, shorter hospital stays, and superior stone-free rates. Together, these two papers underscore a clear clinical mandate: integrating suction into endourological procedures significantly mitigates infectious risks and enhances stone clearance.

Next, we turn to a series of papers addressing the prostate cancer continuum, from risk assessment and active surveillance to surgical approaches and oligometastatic management. We begin with a systematic review and meta-analysis in European Urology Focus that explores an intriguing clinical question: whether male pattern baldness should be incorporated into prostate cancer risk assessments [10]. Evaluating twenty studies encompassing over one hundred fifty-four thousand men, the researchers identified a small but statistically significant association between any baldness pattern and overall prostate cancer risk. This risk was more pronounced for vertex baldness, which carried a nineteen percent increased risk, and for early-onset baldness occurring at or before age thirty, which carried a twenty-six percent increased risk. Furthermore, baldness was associated with a fifteen percent increased risk of more aggressive prostate cancer forms, suggesting that early-onset and vertex baldness could serve as simple, non-invasive clinical biomarkers during early screening discussions. For patients already diagnosed with low-risk disease, the STHLM3-AS NorDCaP trial, published in the BJU International, evaluated the utility of the Stockholm3 blood-based test in predicting disease upgrading during active surveillance biopsies [4]. In a prospective cohort of one hundred ninety-nine men with grade group one prostate cancer, thirty-six percent experienced upgrading to grade group two or higher on surveillance biopsy. The Stockholm3 test demonstrated an area under the curve of zero point seven one, performing comparably to prostate-specific antigen density and multiparametric magnetic resonance imaging. Utilizing a Stockholm3 threshold of fifteen or higher achieved a sensitivity of ninety-three percent and a negative predictive value of eighty-seven percent, which would have spared nineteen percent of patients from undergoing a biopsy while missing only five cases of upgrading, none of which were grade group three or higher. This suggests Stockholm3 can serve as a highly practical, blood-based tool to reduce the burden of repeated biopsies. When active treatment is required, the choice of surgical approach remains a point of discussion. A study in the World Journal of Urology utilized propensity score matching to compare the transperitoneal and extraperitoneal approaches in single-port robot-assisted radical prostatectomy [9]. Analyzing matched cohorts of fifty-five patients per group, the researchers found that the extraperitoneal approach was associated with a shorter hospital stay of one day compared to two days, and lower early postoperative pain scores. However, it also resulted in higher estimated blood loss, averaging one hundred fifty milliliters compared to one hundred milliliters in the transperitoneal group. Importantly, there were no significant differences in operative times, overall complications, short-term oncological outcomes, or the time to urinary continence recovery, indicating that both approaches are clinically feasible and safe. Finally, for patients who progress to oligometastatic castration-resistant prostate cancer, a randomized phase two trial in the BJU International investigated the benefit of metastasis-directed ablative radiotherapy [7]. Thirty patients with up to five metastasis-positive lesions on prostate-specific membrane antigen imaging were randomized to receive either metastasis-directed therapy or observation without altering their systemic therapy. While the proportion of patients with prostate-specific antigen progression at one year did not differ significantly between the groups, the median time to progression was significantly longer in the radiotherapy arm at twelve point four months compared to just two point nine months in the observation arm, suggesting that early ablative intervention can successfully delay disease progression.

Our final theme addresses surveillance in bladder cancer and postoperative complications in penile cancer, emphasizing the need for personalized monitoring and standardized care pathways. Writing in the BJU International, researchers evaluated the utility of serial, tumor-informed circulating tumor DNA testing in fifty-two patients with high-risk non-muscle-invasive bladder cancer [6]. Over the course of surveillance, circulating tumor DNA was detected in thirty-three percent of the cohort. Patients who were positive for circulating tumor DNA had a dramatically higher rate of clinical upstaging compared to those who were negative, at fifty-nine percent versus fourteen percent. Among the subset of patients who underwent radical cystectomy, pathological upstaging was found in seventy-eight percent of the circulating tumor DNA-positive group compared to only eight percent of the negative group. Additionally, distant recurrences occurred exclusively in patients with detectable circulating tumor DNA. These findings suggest that persistent circulating tumor DNA positivity reflects aggressive biology and can identify patients who are unlikely to benefit from continued intravesical salvage therapy, potentially prompting earlier radical intervention. In penile oncology, a national United Kingdom study published in the BJU International investigated the incidence of venous thromboembolism following penile cancer surgery [8]. Analyzing over fifty-nine hundred procedures across more than four thousand patients, the study revealed a cumulative symptomatic venous thromboembolism incidence of zero point two one percent at thirty days, which rose to one point zero eight percent at one hundred eighty days. Higher rates were observed following more extensive procedures, such as total penectomy and inguinal lymph node dissection. Crucially, the majority of these thromboembolic events occurred after hospital discharge. A parallel survey of specialist centers revealed that seventy-one percent of surgeons do not routinely utilize formal risk assessment tools, and prophylaxis practices vary widely. This highlights a critical need for the development of standardized, procedure-specific guidelines advocating for extended post-discharge thromboprophylaxis in high-risk penile cancer patients.

If you only have time for one paper this week, make it the LITESPARK-022 trial published in The New England Journal of Medicine [1]. This phase three trial establishes the disease-free survival benefit of adding belzutifan to adjuvant pembrolizumab for high-risk clear-cell renal cell carcinoma, while highlighting a critical trade-off in treatment-related toxicity that clinicians must navigate.

Here are the key takeaways from this week in Urology. First, the addition of belzutifan to adjuvant pembrolizumab significantly extends disease-free survival in patients with resected, high-risk clear-cell renal cell carcinoma, though at the cost of a substantial increase in grade three or higher toxicities. Second, for upper urinary tract stones measuring two to three centimeters, flexible ureteroscopy with a flexible and navigable suction access sheath is a highly effective, less invasive alternative to mini-percutaneous nephrolithotomy, offering comparable stone-free rates with less blood loss and shorter hospital stays. Third, active suctioning during percutaneous nephrolithotomy maintains lower intrarenal pressures, which translates directly into fewer postoperative infectious complications and improved stone clearance. Fourth, longitudinal circulating tumor DNA testing in high-risk non-muscle-invasive bladder cancer is a powerful predictor of clinical and pathological upstaging, helping identify patients who may need to transition early from intravesical therapy to radical cystectomy. Finally, venous thromboembolism is a significant post-discharge risk after major penile cancer surgery, emphasizing the need for standardized risk assessment and extended thromboprophylaxis protocols.

That's your roundup for This Week in Urology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.